About Bill Anderson
Bill Anderson, CEO of Bayer, has been discussing the challenges facing American farmers, including high input costs and volatile crop prices, stating that many farmers are "at the end of their rope." He has also addressed the company's ongoing litigation over glyphosate, noting that Bayer has faced over 100,000 lawsuits and warning that without a solution, there will be no American-produced glyphosate. Anderson highlighted that the U.S. Supreme Court will hear Bayer's case, calling it a "big milestone for American farmers." He also discussed the company's restructuring, saying Bayer has cut management by two-thirds, reoriented the firm to 90-day cycles, and placed 95% of decision-making at lower levels of the organization.
Anderson reported that Bayer registered sales of €45.6 billion, core earnings per share of €4.91, and reduced net financial debt to €29.8 billion. He stated that the company is again proposing to pay only the statutory minimum dividend. Anderson also discussed Bayer's innovation pipeline, including a new insecticide called Clanaxis and gene-editing technology, while criticizing the European Union for blocking gene editing in plants. He said that if Bayer cannot prove it is the best home for its agriculture, medicines, and consumer health businesses, the company may have to change its structure.
Source: AI-verified profile updated from Bill Anderson's recent appearances.
Browse all interviews →
✨ AI-enhanced transcript with speaker attribution
N
Narrator0:00
Bayer is not among Bayer's top markets, but it is certainly our intention that it will be. That's the word coming in from a Bayer CEO, Bill Anderson. My colleague, Ritu Singh, caught up with him and spoke to him on the Indian markets, artificial intelligence. Listen into a slice of that conversation.
B
Bill Anderson0:20
The growth we've seen in recent years has been tremendous. I mean, we're here today in Bangalore because we're opening an innovation hub. And this innovation hub, it's not back office.
B
Bill Anderson0:31
And it's not just for India. Although we are supporting our rapidly expanding Indian operations from this hub.
B
Bill Anderson0:39
The work we're doing here is supporting the 88,000 people we have around the world.
B
Bill Anderson0:45
And I've seen some amazing results here. Whether it's we're one of the largest providers of imaging solutions.
B
Bill Anderson0:53
So, we've got imaging R&D here in this building. We've got people working on novel applications for pharmaceutical R&D, for crop science, genetics, all here in Bangalore. So, I think we're just going to see a lot more of that in the years ahead.
R
Ritu Singh1:11
Let me ask you how critical the market is for you. As we speak, is it in your top five markets? What's the pecking order? What's your outlook and the kind of growth potential you see here? You've been here for 130 years. You have 13,000 employees. Crop science is the largest business, but what next? What's the growth engine?
B
Bill Anderson1:29
Yeah. I would say today, India's not in the top markets today.
B
Bill Anderson1:36
But it's certainly our every intention that it will be.
B
Bill Anderson1:40
And I'm not talking about in, by the way, 2047, those goals. I'm amazed. And I believe India can do this.
B
Bill Anderson1:50
I've seen the progress you've made. I think this can be reality, but we want India to be a top country for us by 2030.
B
Bill Anderson2:02
Not 2047.
B
Bill Anderson2:03
And so that's why we're investing. We're investing in technology here in Bangalore, but we're investing in manufacturing, R&D, commercial operations, and we're investing in our customers.
R
Ritu Singh2:17
Yeah, to get to having India as one of your top markets by 2030, where are some of these investments across your divisions if I were to ask you? Consumer health is one of the more younger businesses here perhaps. Is that growing faster than the others or what will get you to the top market by 2030?
B
Bill Anderson2:34
They're actually growing at similar levels and we think they're all capable of faster growth. So, I want to answer your question, but the honest answer is we're investing in all three divisions. We're actually not investing more in one than another. We're going in all of them.
B
Bill Anderson2:55
And in pharmaceuticals, for example, you may know this, when people are exposed to intense heat,
B
Bill Anderson3:03
they are more vulnerable to cardiovascular distress and to kidney disease. And so we have a therapy that's in India today. It's expanding rapidly and we now brought new clinical data in heart failure. So, we're investing there and so whether it's consumer health, pharmaceuticals, or crop science, a lot of potential, but oh
